Multiple studies have demonstrated that NF-κB inhibition, both in peripheral immune cells and in the CNS, is protective in EAE, suggesting that pharmacological targeting of the NF-κB pathway might have a therapeutic effect in MS. Here, NFKB1 is linked to myeloid sarcoma.